InvestorsHub Logo
Followers 64
Posts 5750
Boards Moderated 0
Alias Born 07/09/2003

Re: None

Thursday, 08/09/2018 5:13:44 PM

Thursday, August 09, 2018 5:13:44 PM

Post# of 859
BioLife Solutions Announces Second Quarter 2018 Financial Results
PR Newswire
8:15 AM ET
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today reported financial results and operational highlights for the three and six months ended June 30, 2018.

https://mma.prnewswire.com/media/464869/BioLife_Solutions.jpg

Revenue from biopreservation media product sales for the second quarter of 2018 reached a new record of $5.2 million, an increase of 102% from the second quarter of 2017, and an increase of 36% from the first quarter of 2018. Revenue from biopreservation media product sales for the first half of 2018 totaled $9.0 million, an increase of 83% compared with the prior-year period. Product revenue growth for both periods was driven by sales of CryoStor(R) and HypoThermosol(R) clinical-grade biopreservation media to the high-growth cell and gene therapy segment, and to BioLife's worldwide distributor network.

Second Quarter 2018 Financial Results

-- Gross margin for the second quarter of 2018 increased to 70% from 63% in the second quarter of 2017, due to higher average selling prices per liter, and reduced COGS per liter resulti ng from higher production volume driven by increased sales of CryoStor to the regenerative medicine market segment.

-- Operating expenses for the second quarter of 2018 were $2.4 million, compared with $1.9 million for the second quarter of 2017, reflecting higher performance-based compensation expense and increased expenditures related to enhancing our quality management system.

-- Operating profit for the second quarter of 2018 was $1.3 million, compared with an operating loss of $341,000 for the second quarter of 2017.

-- Net income attributable to common stockholders for the second quarter of 2018 was $1.0 million, or $0.05 per diluted share, compared with a net loss attributable to common stockholders of $768,000, or $0.06 per share, for the second quarter of 2017.

-- EBITDA for the second quarter of 2018 was positive $1.2 million compared with negative $514,000 for the second quarter of 2017.

-- Adjusted EBITDA for the second quarter of 2018 was $1.7 million compared with $59,000 for the second quarter of 2017.

-- Cash provided by operations for the second quarter of 2018 was $562,000, compared with cash used by operations of $103,000 for the prior-year period.

-- Cash balance at June 30, 2018 was $14.2 million compared with $2.3 million at June 30, 2017, and $6.7 million at December 31, 2017.

Mike Rice, BioLife President & CEO, commented, "In Q2, we demonstrated our ability to efficiently manage the business during a sustained h igh-growth phase. We continued to see strong demand for our proprietary products in the cell and gene therapy segment, and expect this to continue for the next several quarters based on awareness of our products in this market segment and the number of new clinical trials in process by our customers."

Q2 2018 Market Segment & Channel Highlights

Regenerative Medicine (cell therapy, tissue engineering, stem cell transplant)

-- Product revenue: $3.0 million; 58% of total revenue, with 176% growth over Q2 2017 and 42% growth over Q1 2018.

-- Gained 37 new cell and gene therapy companies in the regenerative medicine market segment.

Distributors

-- Product revenue: $1.7 million; 33% of total revenue with 144% growth over Q2 2017 and 63% growth over Q1 2018.

-- Key worldwide distributors: STEMCELL Technologies, MilliporeSigma, Thermo Fisher and VWR.

Six Month Financial Results

-- Gross margin for the six months ended June 30, 2018 increased to 68% from 62% in the same period last year, due to higher average selling prices per liter, and reduced COGS per liter resulting from higher production volume, driven by increased sales of CryoStor to the regenerative medicine market segment.

-- Operating expenses for the first six months of 2018 were $4.7 million, compared with $3.8 million for the same period in 2017, reflecting higher performance-based compensation expense and increased expenditures related to enhancing our quality management system.

-- Operating profit for the first half of 2018 was $1.4 million, compared with an operating loss of $805,000 for the first half of 2017.

-- Net income attributable to common stockholders for the six months ended June 30, 2018 was $9 43,000, or $0.05 per diluted share, compared with a net loss attributable to common stockholders of $1.6 million, or $0.13 per share, for the same period in 2017.

-- EBITDA for the first six months of 2018 was positive $1.3 million compared with negative $1.1 million for same period in 2017.

-- Adjusted EBITDA for the six months ended June 30, 2018 was $2.3 million compared with $15,000 for the prior year period.

-- Cash provided by operations for first six months of 2018 was $953,000, compared with cash used by operations of $272,000 for the prior-year period.

Roderick de Greef, BioLife Chief Financial Officer, remarked, "Our second quarter financial results mark the first time since inception that BioLife has achieved positive net income, underscoring the operating leverage we can realize on higher revenue levels. Given our strong financial results for the first half of 2018 and our outlook for the remainder of the year, we now expect 2018 to be our first full year of profitability."

2018 Financial Guidance

Management provided 2018 financial guidance as follows:

-- Affirmed guidance for biopreservation media revenue to be between $18.5 million and $20.0 million, representing growth of 68% to 82% over 2017.

-- Revised guidance for gross margin to be between 68% and 70%, up from prior guidance of 63% to 65% and up from 61% in 2017.

-- Revised guidance for operating expenses to between $9.5 million to $10.0 million, up from $9.0 million to $9.5 million and compared with $7.8 million in 2017.

-- Affirmed guidance for full-year GAAP operating profit, with proportional increases in EBITDA, adjusted EBITDA and cash flow from operations.

-- Anticipate full-year 2018 GAAP net income.

Conference Call & Webcast

The Company will host a conference call and live webcast at 10:00 a.m. ET this morning. To access the live webcast, please go to www.biolifesolutions.com and click on the top banner, or directly at www.biolifesolutions.com/earnings/. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 4968357. A webcast replay will be available approximately two hours after the call and will be archived on www.biolifesolutions.com for 90 days.

techisbest

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLFS News